» Articles » PMID: 32050909

Osteoporosis Management in Australian General Practice: an Analysis of Current Osteoporosis Treatment Patterns and Gaps in Practice

Overview
Journal BMC Fam Pract
Publisher Biomed Central
Date 2020 Feb 14
PMID 32050909
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Among Australians aged 50 and over, an estimated 1 in 4 men and 2 in 5 women will experience a minimal trauma fracture during their remaining lifetime. Effective fracture prevention is hindered by substantial undertreatment, even of patients who clearly warrant pharmacological therapy. Poor adherence to osteoporosis treatment is also a leading cause of repeat fractures and hospitalisation. The aim of this study was to identify current osteoporosis treatment patterns and gaps in practice in Australia, using general practice data, and to explore general practitioners' (GPs') attitudes to osteoporosis treatment and their views on patient factors affecting osteoporosis management.

Methods: The study was conducted in two phases. Phase 1 was a longitudinal retrospective cohort study which utilised data from MedicineInsight - a national general practice data program that extracts longitudinal, de-identified patient data from clinical information systems (CISs) of participating general practices. Phase 2 included semi-structured, in-depth telephone interviews with a sample of MedicineInsight practice GPs. Data were analysed using an inductive thematic analysis method informed by the theory of planned behaviour.

Results: A diagnosis of osteoporosis was recorded in 12.4% of patients over the age of 50 years seen in general practice. Of those diagnosed with osteoporosis, almost a quarter were not prescribed osteoporosis medicines. From 2012 to 17, there was a progressive increase in the number of denosumab prescriptions, while prescriptions for bisphosphonates and other osteoporosis medicines decreased. More than 80% of patients who ceased denosumab treatment had no subsequent bisphosphonate prescription recorded. Interviews with GPs revealed beliefs and attitudes that may have influenced their intentions towards prescribing and osteoporosis management.

Conclusions: This study suggests that within the Australian general practice setting, osteoporosis is underdiagnosed and undertreated. In addition, it appears that most patients who ceased denosumab treatment had no record of subsequent antiresorptive therapy, which would place them at risk of further fractures. The study supports the need for the development of clinical education programs addressing GP knowledge gaps and attitudes, and the implementation of specific interventions such as good reminder/recall systems to avoid delays in reviewing and treating patients with osteoporosis.

Citing Articles

Developing and Evaluating an Interactive, Case-Based, Web-Based Active Learning Tool for Primary Care Physicians (Community Fracture Capture Learning Hub): Protocol for an Acceptability and Engagement Study.

Fathalla A, Chiang C, Audehm R, Gorelik A, Chang S, Yates C JMIR Res Protoc. 2025; 14:e57511.

PMID: 39999431 PMC: 11897679. DOI: 10.2196/57511.


Standalone Anterior Lumbar Interbody Fusion Without Supplementary Posterior Fixation Is Effective for Treatment of Symptomatic Grade 1 Isthmic Spondylolisthesis.

Toohey J, Faulks C, Biddau D, Claydon M, Munday N, Malham G Int J Spine Surg. 2024; .

PMID: 39638556 PMC: 11687050. DOI: 10.14444/8663.


The evaluation of an osteoporosis medication management service in community pharmacy, a cohort study.

Phuong J, Manon S, Moles R, Mason D, Vleeskens C, Rezae F Explor Res Clin Soc Pharm. 2024; 15:100488.

PMID: 39318501 PMC: 11419926. DOI: 10.1016/j.rcsop.2024.100488.


Perspectives of healthcare providers on osteoporosis, falls and fracture risk: a systematic review and thematic synthesis of qualitative studies.

Cho C, Bak G, Sumpton D, Richards B, Sherrington C Arch Osteoporos. 2024; 19(1):90.

PMID: 39313605 PMC: 11420259. DOI: 10.1007/s11657-024-01446-8.


Role of bisphosphonates in osteoporosis caused by adult growth hormone deficiency.

Cheng Z, Li J, Chen Z, Ren W Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(6):839-847.

PMID: 39311779 PMC: 11420967. DOI: 10.11817/j.issn.1672-7347.2024.230469.


References
1.
Cummings S, Ferrari S, Eastell R, Gilchrist N, Jensen J, McClung M . Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2017; 33(2):190-198. DOI: 10.1002/jbmr.3337. View

2.
Khosla S, Hofbauer L . Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017; 5(11):898-907. PMC: 5798872. DOI: 10.1016/S2213-8587(17)30188-2. View

3.
Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD001155. DOI: 10.1002/14651858.CD001155.pub2. View

4.
Tobin L, de Almedia Neto A, Wutzke S, Patterson C, Mackson J, Weekes L . Influences on the prescribing of new drugs. Aust Fam Physician. 2008; 37(1-2):78-80, 83. View

5.
Parker D . An audit of osteoporotic patients in an Australian general practice. Aust Fam Physician. 2013; 42(6):423-7. View